Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures

Trial Profile

Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Bumetanide (Primary) ; Phenobarbital
  • Indications Neonatal seizures
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2018.
    • 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top